Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
34.65 ^USD	+8.69%		+7.41%	+51.11%

06-28	Protagonist Therapeutics to Join S&P SmallCap 600	MT
06-14	Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control	CI

PROTAGONIST THERAPEUTICS, INC : Change in Directors or Principal Officers (form 8-K)

January 06, 2023 at 09:33 pm

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Effective January 1, 2023, David Liu, Protagonist Therapeutics, Inc.'s Chief R&D Strategy Officer, transitioned to a part-time R&D Strategy Advisor due to health reasons. In his new role, Dr. Liu is no longer a Section 16 or executive officer.

Latest news about Protagonist Therapeutics, Inc.

Protagonist Therapeutics to Join S&P SmallCap 600	06-28	MT
Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control	06-14	CI
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing	06-11	MT
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing	06-11	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	04-03	MT
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	03-26	CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	03-18	CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	03-11	MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	03-11	CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	03-04	MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	03-04	MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	03-04	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating	02-28	MT
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	01-31	DJ
Transcript : Protagonist Therapeutics, Inc. - Special Call	01-31
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	01-31	CI
Transcript : Protagonist Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM	01-09
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing	12-15	MT
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial	12-13	MT
Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis	12-13	CI
Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib	11-27	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI

Chart Protagonist Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (Î±4Î²7) specific integrin antagonist for inflammatory bowel disease (IBD).

Sector

Biotechnology & Medical Research

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Protagonist Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.65 USD

Average target price

43.83 USD

Spread / Average Target

+26.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTAGONIST THERAPEUTICS, INC.	+51.11%	2.03B
MODERNA, INC.	+19.41%	45.51B
IQVIA HOLDINGS INC.	-8.62%	38.52B
LONZA GROUP AG	+38.65%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	30.74B
CELLTRION, INC.	-13.50%	26.03B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.92B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.13B
MEDPACE HOLDINGS, INC.	+34.36%	12.73B
BIO-TECHNE CORPORATION	-7.14%	11.29B

Other Biotechnology & Medical Research